Bli medlem
Bli medlem

Du är här


IDL Biotech: Redeye: IDL Biotech - Good growth prospects

Redeye raise our base case for IDL on the back of strong Q4'19
performance. Sales volumes are developing favorably and the company
delivered black figures from its operations in the quarter. We view
the future outlook as promising with continued good growth prospects
and see several changes in market dynamics in IDL's favor. We believe
there is some further upside in the stock despite the strong recent
rally, as investors are starting to buy into the long-term story.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.